Inclusion Criteria:
1. Histologically confirmed malignant solid tumor (including neuroblastoma, soft tissue
sarcoma, osteosarcoma, Ewing Sarcoma, and Wilms tumor) with evidence of incurable
disease and tumor recurrence/progression after all available curative standard
therapies.
1. Subjects with neuroblastoma must have received or be intolerant to anti-GD2
antibody therapy.
2. Subjects with Wilm's tumor must have received or be intolerant to ifosfamide or
cyclophosphamide plus etoposide therapy or alternative salvage regimen.
3. Subjects with embryonal rhabdomyosarcoma must have received or be intolerant to
Adriamycin-based therapy.
4. Subjects with surgically resected pulmonary osteosarcoma in first recurrence
must have received surgical resection of metastatic nodules.
2. Subjects during dose escalation must have evaluable or measurable disease. Subjects
during dose expansion must have measurable disease, except neuroblastoma which may
have MIBG positive disease only.
3. B7-H3 positive expression on malignant cells is NOT required but archival tissue
must be available, or the subject must be willing to undergo tissue biopsy for
expression analysis.
4. Age: Must be ≥ 2 and < 26 years of age.
* For the first three subjects treated with B7 H3CART, must be ≥ 12 and < 26 years
of age.
5. Performance Status: Patients > 16 years of age must have Karnofsky ≥ 50%. Patients ≤
16 years of age must have Lansky scale ≥ 50%; or ECOG performance status ≤ 2 (see
Appendix A. PERFORMANCE STATUS CRITERIA).
6. Prior Therapy. 1. No limit to the number of prior therapies.
2. Prior Therapy Wash-out: At least 2 weeks or 5 half lives, whichever is shorter,
must have elapsed since any prior systemic therapy at the time the subject is
planned for leukapheresis, except for systemic inhibitory/stimulatory immune
checkpoint therapy, which requires 5 half lives. Radiation therapy must have
been completed at least 3 weeks prior to enrollment, with the exception that
there is no time restriction if the subject has measurable/evaluable disease
outside the radiation port or the site of radiation has documented progression.
7. Normal Organ and Marrow Function (supportive care is allowed per institutional
standards, i.e. filgrastim, transfusion)
- - ANC ≥ 750/uL*
- Platelet count ≥ 75,000/uL*
- Absolute lymphocyte count ≥ 150/uL*
- Adequate renal, hepatic, pulmonary and cardiac function defined as:
- Creatinine within institutional norms for age (i.e. ≤ 2 mg/dL in adults or
according to table below in children <18 years) OR creatinine clearance
(as estimated by Cockcroft Gault Equation) ≥ 60 mL/min.
Age (Years): ≤5 Maximum Serum Creatinine (mg/dL): 0.8 Age (Years): 5 < age ≤ 10
Maximum Serum Creatinine (mg/dL): 1.0 Age (Years): >10-18 Maximum Serum Creatinine
(mg/dL): 1.2 Age (Years): > 18 Maximum Serum Creatinine (mg/dL): 2.0.
- - Serum ALT/AST ≤ 2.5x ULN (unless elevated ALT/AST is associated with disease
involvement of the liver, in which case this criterion will be waived and not
disqualify a patient).
- - Total bilirubin ≤ 1.5 mg/dl, except in subjects with Gilbert's syndrome.
- - Cardiac ejection fraction ≥ 45%, no evidence of physiologically
significant pericardial effusion as determined by an ECHO,
- No clinically significant ECG findings.
- - No clinically significant pleural effusion.
- - Baseline oxygen saturation > 92% on room air.
- - if cytopenias are not judged by the investigator to be due to
underlying disease (i.e. potentially reversible with anti-neoplastic
therapy); A subject will not be excluded because of pancytopenia ≥
Grade 3 if it is due to disease, based on the results of bone marrow
studies.
8. Females of childbearing potential must have a negative serum or urine pregnancy test
(females who have undergone surgical sterilization or who have been postmenopausal
for at least 2 years are not considered to be of childbearing potential).
9. Subjects of child bearing or child fathering potential must be willing to practice
birth control from the time of enrollment on this study and for four
- (4) months
after receiving the preparative regimen or for as long as CAR T cells are detectable
in peripheral blood.
10. Must provide informed consent. For subjects <18 years old, or adults with limited
decision-making capacity, their legal authorized representative (LAR) (i.e. parent
or guardian) must give informed consent. Pediatric subjects will be included in age
appropriate discussion and assent will be obtained for those > 7 years of age, when
appropriate. If a minor becomes of age during participation of this study, he/she
will be asked to reconsent as an adult.
Exclusion Criteria:
1. Receiving any other current investigational agents.
2. History of other malignancy, except non-melanoma skin cancer or carcinoma in situ
(e.g. cervix, bladder, breast), unless disease free for at least 3 years.
3. Presence of untreated brain metastases will be excluded. Subjects with previous CNS
tumor involvement that has been treated and is stable for at least 3 months
following completion of therapy are permitted. Patients who are clinically stable as
evidenced by no requirements for corticosteroids, no evolving neurologic deficits,
and no progression of residual brain abnormalities without specific therapy, are
permitted.
4. Presence of fungal, bacterial, viral, or other infection that is uncontrolled.
Simple UTI and uncomplicated bacterial pharyngitis are permitted if responding to
active treatment.
5. Ongoing infection with HIV or hepatitis B (HBsAg positive) or hepatitis C virus
(anti HCV positive) as the immunosuppression contained in this study will pose
unacceptable risk. A history of hepatitis B or hepatitis C is permitted if the viral
load is undetectable per quantitative PCR and/or nucleic acid testing.
6. History of myocardial infarction, cardiac angioplasty or stenting, unstable angina,
or other clinically significant cardiac disease within 12 months of enrollment.
7. Any medical condition that in the judgement of the sponsor investigator is likely to
interfere with assessment of safety or efficacy of study treatment.
8. History of severe immediate hypersensitivity reaction to any of the agents used in
this study.
9. Pregnant females are excluded from this study because the effects of autologous
B7-H3CART on the developing human fetus are unknown and because the chemotherapy
agents used in this trial (cyclophosphamide and fludarabine) are category D agents
with the potential for teratogenic or abortifacient effects. Additionally, because
there is an unknown but potential risk for adverse events (AEs) in nursing infants
secondary to treatment of the mother with cyclophosphamide/fludarabine,
breastfeeding should be discontinued if the mother is treated with
cyclophosphamide/fludarabine. These potential risks may also apply to other agents
used in this study.
10. Primary immunodeficiency or history of systemic autoimmune disease (e.g., Crohns,
rheumatoid arthritis, systemic lupus) requiring systemic immunosuppression/systemic
disease modifying agents within the last 2 years.
11. Patients who require systemic corticosteroid or other immunosuppressive therapy. (A
one-week washout from systemic corticosteroid or other immunosuppressive therapy is
permitted.) Use of physiologic doses of corticosteroids (up to 3 mg/m2/day
prednisone equivalent) are permitted. Use of topical, ocular, intra-articular,
intra-nasal, or inhaled corticosteroids are permitted.
12. In the investigator's judgment, the subject is unlikely to complete all protocol
required study visits or procedures, including follow up visits, or comply with the
study requirements for participation.
